Assessment of Intratumoral Heterogeneity in Isolated Human Primary High-Grade Glioma: Cluster of Differentiation 133 and Cluster of Differentiation 15 Double Staining of Glioblastoma Subpopulations
Keywords:Glioblastoma, Gliomas Stem Cells, Subpopulations, CD133, CD15
BACKGROUND: Gliomas are the most common primary brain tumors, representing 50–60% of malignant primary brain tumors. Gliomas are highly heterogeneous with marked inter- and intratumoral diversity. Gliomas heterogeneity is a challenging issue in the development of personalized treatment. The simplest method for studying heterogeneity is using ex vivo cell cultures; in our case, the cell lines were isolated from patient with glioblastomas.
AIM: Here, we reported distinct cell subpopulations heterogeneity in glioblastoma cells.
METHODS: Human glioblastoma cells isolation is conducted by enzymatic method with combination of collagenase I, hyaluronidase, and trypsin enzyme in proportional amount from patient. Immunostaining was performed to assess glial fibrillary acidic protein (GFAP), Ki-67, isocitrate dehydrogenase-1 (IDH-1) status, and program death ligand-1 (PD-L1) expression. Primary glioblastoma cell line was characterized by flow cytometry (fluorescence-activated cell sorting) analysis based on cluster of differentiation (CD) 133 and CD15 marker expression. U87MG and CGNH-89 cell lines were used as control. Distinct subpopulation analysis was performed by double staining of CD133 and CD15 in isolated primary glioblastoma cell line and its comparative control cells.
RESULTS: Our isolated glioblastoma cells morphology was adherent cells which were able to form spheres depending on environment. Immunostaining confirmed GFAP, Ki-67, IDH-1 mutants, and PD-L1 expression. Our isolated glioblastoma cells expressed CD133 and CD15, coexpressed CD133/CD15 in different patterns. The highest subpopulation in primary glioblastoma was CD133+/CD15+.
CONCLUSION: Glioblastoma cells can be isolated using enzymatic methods. Isolated glioblastoma cells consist of four different subpopulations distinguished by CD133/CD15 double staining. Intratumoral heterogeneity exists and directly or indirectly depends on their microenvironment.
Plum Analytics Artifact Widget Block
Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(Suppl 5):v1-49. https://doi.org/10.1093/neuonc/nos218 PMid:23095881
Alves TR, Lima FR, Kahn SA, Lobo D, Dubois LG, Soletti R, et al. Glioblastoma cells: A heterogeneous and fatal tumor interacting with the parenchyma. Life Sci 2011;89:532-9. https://doi.org/10.1016/j.lfs.2011.04.022 PMid:21641917
Dirks PB. Brain tumor stem cells: The cancer stem cell hypothesis writ large. Mol Oncol. 2010;4(5):420-30. https://doi.org/10.1016/j.molonc.2010.08.001 PMid:20801091
Martin-Hijano L, Sainz B. The interactions between cancer stem cells and the innate interferon signaling pathway. Front Immunol. 2020;11:526. https://doi.org/10.3389/fimmu.2020.00526 PMid:32296435
Dimov I, Tasić-Dimov D, Conić I, Stefanovic V. Glioblastoma multiforme stem cells. Sci World J. 2011;11:930-58. https://doi.org/10.1100/tsw.2011.42
Jin X, Jin X, Jung JE, Beck S, Kim H. Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun 2013;433(4):496-501. https://doi.org/10.1016/j.bbrc.2013.03.021 PMid:23524267
Sundar SJ, Hsieh JK, Manjila S, Lathia JD, Sloan A. The role of cancer stem cells in glioblastoma. Neurosurg Focus. 2014;37(6):E6. https://doi.org/10.3171/2014.9.focus14494 PMid:25434391
Faried A, Arifin MZ, Ishiuchi S, Kuwano H, Yazawa S. Enhanced expression of proapoptotic and autophagic proteins involved in the cell death of glioblastoma multiforme induced by synthetic glycans. J Neurosurg. 2014;120(6):1298-308. https://doi.org/10.3171/2014.1.jns131534 PMid:24678780
Widowati W, Heriady Y, Laksmitawati DR, Jasaputra DK, Wargasetia TL, Rizal R, et al. Isolation, characterization and proliferation of cancer cells from breast cancer patients. Acta Inform Med. 2019;26(4):228-32. https://doi.org/10.5455/aim.2018.26.240-244
Kahlert UD, Bender NO, Maciaczyk D, Bogiel T, Bar EE, Eberhart CG, et al. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component. Folia Neuropathol. 2012;50(4):357-68. https://doi.org/10.5114/fn.2012.32365 PMid:23319191
Pavon LF, Marti LC, Sibov TT, Miyaki LA, Malheiros SM, Mamani JB, et al. Isolation, cultivation and characterization of CD133+ stem cells from human glioblastoma. Einstein (Sao Paulo). 2012;10(2):197-202. https://doi.org/10.1590/s1679-45082012000200013 PMid:23052455
Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, et al. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget. 2015;6(30):30232-8. https://doi.org/10.18632/oncotarget.4920 PMid:26338964
Chen RQ, Liu F, Qiu XY, Chen XQ. The prognostic and therapeutic value of PD-L1 in glioma. Front Pharmacol. 2019;9:1503. PMid:30687086
Goyal R, Mathur SK, Gupta S, Goyal R, Kumar S, Batra A, et al. Immunohistochemical expression of glial fibrillary acidic protein and CAM5.2 in glial tumors and their role in differentiating glial tumors from metastatic tumors of central nervous system. J Neurosci Rural Pract. 2015;6:499-503. https://doi.org/10.4103/0976-3147.168426 PMid:26752892
Veganzones S, de la Orden V, Requejo L, Mediero B, González ML, del Prado N, et al. Genetic alterations of IDH1 and VEGF in brain tumors. Brain Behav. 2017;7(9):e00718. https://doi.org/10.1002/brb3.718 PMid:28948065
Ahmed SI, Javed G, Laghari AA, Bareeqa SB, Farrukh S, Zahid S, et al. CD133 Expression in glioblastoma multiforme: A literature review. Cureus. 2018;10(10):e3439. https://doi.org/10.7759/cureus.3439 PMid:30555755
Brown DV, Filiz G, Daniel PM, Hollande F, Dworkin S, Amiridis S, et al. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PLoS One. 2017;12(2):e0172791. https://doi.org/10.1371/journal.pone.0172791 PMid:28241049
Wu X, Wu F, Xu D, Zhang T. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. J Neurooncol. 2016;127(2):221-32. https://doi.org/10.1007/s11060-015-2039-z PMid:26757925
Brescia P, Richichi C, Pelicci G. Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J Oncol 2012;2012:376894. https://doi.org/10.1155/2012/376894 PMid:22685459
Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17(4):362-75. https://doi.org/10.1016/j.ccr.2009.12.049 PMid:20385361
Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol. 2017;134(3):505-12. PMid:28233083
How to Cite
Copyright (c) 2021 Ahmad Faried, Wahyu Widowati, Rizal Rizal, Hendrikus M. B. Bolly, Danny Halim, Wahyu S. Widodo, Satrio H. B. Wibowo, Rachmawati Noverina, Firman P. Tjahjono, Muhammad Zafrullah Arifin (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.
Kementerian Riset Teknologi Dan Pendidikan Tinggi Republik Indonesia
Grant numbers No. 16/E1/KPT/2020 for Basic Research